Towerview LLC reduced its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) by 50.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 70,000 shares of the company’s stock after selling 70,000 shares during the period. Corvus Pharmaceuticals comprises approximately 0.7% of Towerview LLC’s holdings, making the stock its 12th largest position. Towerview LLC owned approximately 0.08% of Corvus Pharmaceuticals worth $1,024,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in CRVS. Quarry LP purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at $27,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Corvus Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after purchasing an additional 748 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Corvus Pharmaceuticals in the third quarter worth $49,000. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals during the second quarter valued at $52,000. Finally, Bayesian Capital Management LP bought a new position in shares of Corvus Pharmaceuticals during the second quarter valued at $70,000. 46.64% of the stock is owned by institutional investors.
Corvus Pharmaceuticals Stock Performance
Shares of NASDAQ:CRVS opened at $14.27 on Friday. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -27.44 and a beta of 0.82. The stock’s 50-day simple moving average is $13.31 and its two-hundred day simple moving average is $14.66. Corvus Pharmaceuticals, Inc. has a 52-week low of $3.96 and a 52-week high of $26.95.
Insider Transactions at Corvus Pharmaceuticals
In other Corvus Pharmaceuticals news, Director David Scott Moore bought 21,700 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the transaction, the director owned 21,700 shares of the company’s stock, valued at $250,201. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.70% of the company’s stock.
Analyst Upgrades and Downgrades
CRVS has been the subject of several research analyst reports. Weiss Ratings downgraded Corvus Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th. The Goldman Sachs Group began coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $33.33.
Get Our Latest Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
Featured Articles
- Five stocks we like better than Corvus Pharmaceuticals
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report).
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
